Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (138 reviews)

For research use only.

Catalog No.S1091

138 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 138 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):564

PubMed: 34075028 ( click the link to review the publication )

Biochem J, 2021, 478(11):2059-2079

PubMed: 34002209 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01028-8

PubMed: 33403501 ( click the link to review the publication )

Cell Signal, 2021, 80:109911

PubMed: 33422645 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)621

PubMed: 33557316 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Theranostics, 2020, 10(26):12204-12222

PubMed: 33204338 ( click the link to review the publication )

Cell Rep, 2020, 33(3):108293

PubMed: 33086062 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3717

PubMed: 33322337 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )
FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Mol Neurobiol, 2020, 57(3):1570-1593

PubMed: 31797328 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

J Agric Food Chem, 2019, 67(34):9510-9521

PubMed: 31382738 ( click the link to review the publication )

Biochimie, 2019, 163:108-116

PubMed: 31185266 ( click the link to review the publication )

Mol Med Rep, 2019, 19(4):2825-2830

PubMed: 30720075 ( click the link to review the publication )

Exp Ther Med, 2019, 17(3):1663-1669

PubMed: 30867686 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )
Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Cell Signal, 2018, 52:12-22

PubMed: 30138697 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2364

PubMed: 28539593 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4119

PubMed: 28646158 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )
Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )
Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Neoplasia, 2014, 16(10):824-34

PubMed: 25379019 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
A4-Fuk	M4TRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV7JR\|UxRTBwMEK4NFYh\|ryP	NWLuRZl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{CyZWlEPTB;MD6wN\|g{PSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-11	M4nnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TQdGlEPTB;MD6wO\|gzOiEQvF2=	M4nyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-1	NUnQd\|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmruTWM2OD1yLkC4OVg2KM7:TR?=	MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HMV-II	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NU\yRVd2UUN3ME2wMlA5QDR4IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-205	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4fnUWlEPTB;MD6xNFQ2PCEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES1	M4L6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\QXmlEPTB;MD6xNFY6PiEQvF2=	MkfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GDM-1	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWXMTY17UUN3ME2wMlE{Pjd{IN88US=>	MoiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ML-2	NF\C[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NID0eW1KSzVyPUCuNVU5QTZizszN	NH32NZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Saos-2	NYP3foZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTBwMU[1NlYh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPPWYtKSzVyPUCuNVgyOzVizszN	M1SzRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
G-401	NVTme4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYDJR\|UxRTBwMUiyN{DPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EW-16	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWrhN5ZbUUN3ME2wMlE5Pzd5IN88US=>	M1\zOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-7	NHfxOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTBwMUi4PFEh\|ryP	NVT2T\|BERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H727	NVnTbHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3X5W2lEPTB;MD6xPVc6PCEQvF2=	NXz5cmhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LCLC-97TM1	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4SwOGlEPTB;MD6yNFk2PSEQvF2=	MlzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H650	NWrhdVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mk\kTWM2OD1yLkKxN\|g1KM7:TR?=	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2122	NVn6eIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoT2TWM2OD1yLkKzNlk6KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	NEPp[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV;JR\|UxRTBwMkO2PVgh\|ryP	NXX6VWZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HT-29	MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{j0cWlEPTB;MD6yOFI1QCEQvF2=	NXPKPGtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB771-HNC	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF;vS3ZKSzVyPUCuNlU6OTVizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-144	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{n2SWlEPTB;MD6yOlE6OSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LAN-6	M1q4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXKyXIdzUUN3ME2wMlI3OzR6IN88US=>	NX\QU3pxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EW-18	NYHPT2RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYHJR\|UxRTBwMkewNFEh\|ryP	M1jaWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LS-1034	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFj1ZVRKSzVyPUCuNlcyOzJizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EW-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm[5TWM2OD1yLkK4OFMzKM7:TR?=	NF;UOmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-C1	M2DPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moj4TWM2OD1yLkK5N\|E{KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RS4-11	NWLGT4xXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoC1TWM2OD1yLkOzO\|U5KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES4	NEHZRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrCTWM2OD1yLkSxNFM5KM7:TR?=	NE\jcFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYrJR\|UxRTBwNEGzOlgh\|ryP	NH3NNXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUPJR\|UxRTBwNEW0N\|ch\|ryP	M1fjd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BFTC-905	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkS0TWM2OD1yLkS2O\|U5KM7:TR?=	Ml6zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
A375	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlXKTWM2OD1yLkS3OlE4KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SJRH30	M375dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LUbmlEPTB;MD61NFgzOiEQvF2=	MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NOS-1	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4jKZmlEPTB;MD61NlI3PyEQvF2=	M4\lc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SIG-M5	NFWzV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVnZT2d3UUN3ME2wMlU{PTV5IN88US=>	NFzEXo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DOK	NY\kWZc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nGdGlEPTB;MD61OVYh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NB69	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHvRXJNKSzVyPUCuOVgzPTdizszN	NFexZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-NEP-1	NVHtWJh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrXUppKSzVyPUCuOlAzOzZizszN	M4PuNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-MM-2	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\DPG8zUUN3ME2wMlY2PDlzIN88US=>	M1zVSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H358	NWrwWIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlnoTWM2OD1yLk[3NFgzKM7:TR?=	NVSxNVc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RH-1	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVT3eZlHUUN3ME2wMlc1QDV7IN88US=>	NEjp[pk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NH-12	NHz3PG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mm\lTWM2OD1yLke2NFQ3KM7:TR?=	NEDDNIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TE-12	M12xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHzQSXVKSzVyPUCuO\|Y1QDZizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-668	NETiNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkDiTWM2OD1yLki0OlY3KM7:TR?=	NG\sc3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
PANC-08-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXf6V4NIUUN3ME2wMlg3Ozd5IN88US=>	M2\SXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HCC2998	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\4cmlEPTB;MD64PFI3OyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ABC-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1W2[2lEPTB;MD65NFM2OiEQvF2=	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ES6	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVnJR\|UxRTBwOUGwOlYh\|ryP	NUfQ[mE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNU-387	NXjGNZdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTNSnBKSzVyPUCuPVk{QTNizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CMK	NYDKUpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnnSTWM2OD1yLkm5PVI6KM7:TR?=	NHjtOXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SJSA-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXyxZWlXUUN3ME2xMlA{PjV\|IN88US=>	NFvQZng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SIMA	NEHEflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3LqXGlEPTB;MT6wOlgzPSEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES3	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmXvTWM2OD1zLkGyNlk4KM7:TR?=	NEL6PZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
IGROV-1	NV;QTpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWHJR\|UxRTFwMUW0OFQh\|ryP	M2excVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MEL-JUSO	NIHIelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnvYTWM2OD1zLkG1O\|U6KM7:TR?=	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
T84	NHr3eWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGWxU41KSzVyPUGuNlA6OTRizszN	M4jS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAL-85-1	NEPlWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXzk[FNQUUN3ME2xMlI{OTN6IN88US=>	NE\qeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
RD	NGXsR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTFwMk[0OVUh\|ryP	M3Ha[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-8	NI\QPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUDCc2tmUUN3ME2xMlMyPDZ{IN88US=>	NH3NSGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
L-363	NYPtOY85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnPclVKSzVyPUGuN\|QzODhizszN	NGPq[pA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EKVX	NICxZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVLpfW9NUUN3ME2xMlM1PTZ6IN88US=>	MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-MEL-3	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrvO3U1UUN3ME2xMlQ5PTV4IN88US=>	MkP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TGBC24TKB	NIGzbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWrIT4Q1UUN3ME2xMlUxOTl\|IN88US=>	NXm0UHg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1770	NXvM[5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXniNmNOUUN3ME2xMlUyOTF\|IN88US=>	M1znSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HuH-7	NHPGcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1nMbGlEPTB;MT62NFA6QCEQvF2=	M4j4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HL-60	M4fQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{jYRmlEPTB;MT62OlkzQCEQvF2=	NWDOPW9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
TE-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TpSGlEPTB;MT63NFk1PSEQvF2=	NF;zfJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LC-2-ad	NH7sVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXzJR\|UxRTFwN{O4PFch\|ryP	MmLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB647-SCLC	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXvJR\|UxRTFwN{[1PFMh\|ryP	NX7oem9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2171	NUDzRXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTiTWM2OD1zLke3O\|E3KM7:TR?=	NXrIU5o4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-PN-DW	NHP2TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTFwOUGyPVgh\|ryP	M{G5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MC-IXC	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGXWSHVKSzVyPUGuPVg6QCEQvF2=	M{PpXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LS-513	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LiWGlEPTB;Mj6wOVMxPSEQvF2=	M124NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-3	NGXzOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYXt[od3UUN3ME2yMlA6QDR2IN88US=>	MmPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
OPM-2	NIX5XXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlzPTWM2OD1{LkGwNkDPxE1?	NUi5O5NxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LP-1	NXi2Ro1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUGyOoJTUUN3ME2yMlI2QDB5IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-134-A	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYTJR\|UxRTJwMke3JO69VQ>?	MlfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CP66-MEL	MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1q1WmlEPTB;Mj6yPVAyPCEQvF2=	M2f2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HCC1143	M4H5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzzTG5[UUN3ME2yMlQ2OzZ6IN88US=>	M1TuelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LOXIMVI	M2rIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3NeZhKSzVyPUKuOlAzOSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-10	NHLteIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkHVTWM2OD1{LkewPFM5KM7:TR?=	NXfSRmZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1882	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUfJR\|UxRTJwN{WyNlch\|ryP	M{jYdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CHP-126	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3X3b2lEPTB;Mj63OlMyPyEQvF2=	NEixS2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1623	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYTSVGUyUUN3ME2yMlkzODJ2IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GB-1	Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PJSmlEPTB;Mj65N\|QxPCEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RCC10RGB	M3nFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnXWTWM2OD1{Lkm1NlgyKM7:TR?=	M3i1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2141	MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnfsTWM2OD1{Lkm2PFk3KM7:TR?=	NF3pbVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GI-ME-N	NF3DTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWHofGtNUUN3ME2zMlAxPTZ3IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H526	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2TWemlEPTB;Mz6wOFA5PSEQvF2=	NIjvc4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H747	NHLGWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWDJR\|UxRTNwMES5PVIh\|ryP	NWHPe4c4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNU-423	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXvJR\|UxRTNwMkCzNVMh\|ryP	NXXGNnl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A427	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXjJR\|UxRTNwMkW2PVkh\|ryP	NGPmdZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAL-12T	NVfpZ5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnvKTWM2OD1\|LkSwO\|E{KM7:TR?=	NH;QR5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LU-99A	NICxfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXTJR\|UxRTNwNEexNFUh\|ryP	MnzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MS-1	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\LTWM2OD1\|LkWzOFI6KM7:TR?=	M4HpV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-LU-1	NUfrdW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV3JR\|UxRTNwN{[yPVUh\|ryP	Mkf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW837	M{jLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NU\VdYVZUUN3ME2zMlc3OzN\|IN88US=>	MoL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ES8	NHHD[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fuPGlEPTB;Mz64N\|g4PyEQvF2=	M{K2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MZ2-MEL	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPIcW9KSzVyPUOuPVIxQDZizszN	Mk[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TGW	M2nrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWPJR\|UxRTRwMEGzNVEh\|ryP	MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GP5d	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3nSfmlEPTB;ND6wOVM3OiEQvF2=	NHHubXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BB49-HNC	NHTEXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGX6fGVKSzVyPUSuNVUzOTNizszN	MlfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NB13	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGTVNJVKSzVyPUSuNlY5QDdizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	M3LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlfUTWM2OD12LkK4OlE2KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1648	M{nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnThTWM2OD12LkK5PFE6KM7:TR?=	M3[yU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LCLC-103H	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2HwemlEPTB;ND6zNlE6PSEQvF2=	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LS-411N	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmX1TWM2OD12LkS0PFg2KM7:TR?=	NVeyUYdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1092	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3npc2lEPTB;ND60OVY5PyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
PANC-10-05	M3jXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4DpSmlEPTB;ND62PVg1KM7:TR?=	M{DJOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
DK-MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWHJR\|UxRTRwOEC5N\|Mh\|ryP	MmLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
OVCAR-5	NXS0bIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVTJR\|UxRTRwOEGyNlYh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CAL-39	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHHYbY1KSzVyPUSuPFc3PyEQvF2=	NGrP[4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TE-441-T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\oXpBKSzVyPUSuPVA2OzdizszN	M1vmSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MOLT-16	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmXhTWM2OD12Lkm1NlU{KM7:TR?=	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MCF7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHrsV4FKSzVyPUWuNVQ2OTdizszN	NHTSd2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAPAN-1	NIXKTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2jpWmlEPTB;NT6yOVcxPyEQvF2=	M2ruNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PSN1	M2HiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGHVNJhKSzVyPUWuNlczOzVizszN	MoDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H292	NHft[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37yNmlEPTB;NT6zNFA1PCEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CPC-N	NFzmTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmPCTWM2OD13LkO5OFE6KM7:TR?=	NXjxPJJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
DoTc2-4510	NXTjcnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DVeGlEPTB;NT60OVM4OSEQvF2=	NWLmSZEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB1047-RCC	NX:x[JlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXXJR\|UxRTVwNUW5N\|Mh\|ryP	M{fvcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MHH-ES-1	NVHsVmR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVXQZ\|lCUUN3ME21MlU6QTB5IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NMC-G1	NIDMXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTVwN{CyNlch\|ryP	NGjpeoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1710	NYXsT405T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLFeVlpUUN3ME21Mlc1PzVzIN88US=>	M3qxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
YAPC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHHB[oxKSzVyPUWuO\|YzODFizszN	NEm5R5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
22RV1	NUDKdYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIrsOm1KSzVyPUWuPFAxOTlizszN	MoTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-679	NH3RUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUj5OHJMUUN3ME21Mlg5QTR6IN88US=>	MkPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TCCSUP	NYjEdYtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoX4TWM2OD13LkmzNlU6KM7:TR?=	M3LDS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
C2BBe1	M1zvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1PsXmlEPTB;NT65N\|k4KM7:TR?=	M{XzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-15	M2DDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmTETWM2OD14LkC2OlA2KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SCLC-21H	NUfQOoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHudmQ{UUN3ME22MlExQDR\|IN88US=>	M4e5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EoL-1-cell	NYLP[5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYf3dnN{UUN3ME22MlE3PTZ\|IN88US=>	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NKM-1	M2Tnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHv2NVhKSzVyPU[uNVY4OSEQvF2=	NVzpTHJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1304	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3;yXmlEPTB;Nj6yO\|QzQCEQvF2=	M2PFNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NB6	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYr5cYhtUUN3ME22MlI6PjJ{IN88US=>	NGH0PW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NALM-6	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3HyNGlEPTB;Nj6zN\|I{KM7:TR?=	NF3ZPWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H522	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXXJR\|UxRTZwM{OzNFYh\|ryP	M{HiPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MV-4-11	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVT3d4ZCUUN3ME22MlM4ODd7IN88US=>	M3\0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LB2241-RCC	NXjXSpBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoDhTWM2OD14LkO4OlY4KM7:TR?=	M2rBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1417	NIrHZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWDJR\|UxRTZwNEC4OFch\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-1197	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTZwNUexNlIh\|ryP	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
P30-OHK	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MojwTWM2OD14Lk[yO\|ch\|ryP	NXLoUo5JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ALL-PO	M1rsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlv6TWM2OD14LkexPVE3KM7:TR?=	NH7ZTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OVCAR-4	M2LpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoL2TWM2OD14Lke1OFA2KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HCC2157	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPpcmtKSzVyPU[uO\|c1PzVizszN	M{TWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H838	NFzzTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2TDZ2lEPTB;Nj65OlQ6KM7:TR?=	NETIeYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1299	M2e4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWfTOnVqUUN3ME22Mlk4ODlizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW954	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHLTWM2OD15LkKwNFY5KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H441	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnVTWM2OD15LkO0NFY2KM7:TR?=	NUfsbVExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MEL-2	M4XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVmz[2VoUUN3ME23MlQ5Ozd\|IN88US=>	NYrzXZZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KARPAS-45	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7rPGhuUUN3ME23MlY2QTJ7IN88US=>	NHjR[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAL-54	NGPIZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHHGOVhKSzVyPUeuPFI6PzdizszN	MkLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KYSE-180	NGXOb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1qwb2lEPTB;Nz64PFk1OSEQvF2=	Ml76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H187	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MontTWM2OD15Lkm1PVQ4KM7:TR?=	NHznWWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
RT-112	NIDTZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWDTcGQyUUN3ME24MlA6Pjd5IN88US=>	NHv2SJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1437	NX\VPWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnCVFNXUUN3ME24MlA6Pzl3IN88US=>	NYrwb3FsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNU-449	NGPvfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUfJR\|UxRThwMkiyO\|Ih\|ryP	M4LGTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HCC1187	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRThwMkmzPVEh\|ryP	NW\aWY1GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2030	M1nvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX;JR\|UxRThwM{e3NVQh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HuO-3N1	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHLNWXBKSzVyPUiuN\|c5PDRizszN	NWfWeI9zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COLO-792	NWrnU5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUDJR\|UxRThwNEG1Nlch\|ryP	MkjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MIA-PaCa-2	NVX2SFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{PFTWlEPTB;OD64OVUxQCEQvF2=	M4n3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-N-FI	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3TvdGlEPTB;OT6wOFI2KM7:TR?=	M1vyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MMAC-SF	NVeyWopvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHK0c4JKSzVyPUmuNFk4PTFizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H28	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVjTWZhzUUN3ME25MlExPDZ7IN88US=>	Mki5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ETK-1	M1XJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\Fb25KSzVyPUmuNlk6PzRizszN	M321XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1993	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfWVm5KSzVyPUmuOFQzPjFizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
no-11	M3PEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRTlwNEexNkDPxE1?	M2ewZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ChaGo-K-1	NYjiV2tPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1j2WmlEPTB;OT61NVU5OyEQvF2=	NFrE[GM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCCIT	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zGPGlEPTB;OT61N\|E3QSEQvF2=	MnHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SAS	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRTFyLkK0PEDPxE1?	NFXVRWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A673	NXzNNHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLuU45PUUN3ME2xNE4{PzB2IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1522	NXLOT41ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTFyLkO3NFch\|ryP	NYPTWWliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H810	M{DxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmTuTWM2OD1zMD6zPVA4KM7:TR?=	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IST-MES1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jkbmlEPTB;MUCuOFU3PCEQvF2=	M4noSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GR-ST	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF7SRWhKSzVyPUGwMlUxOjRizszN	MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SUP-T1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITYRWpKSzVyPUGwMlc{OTdizszN	NGXxV489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB5	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzp[G5LUUN3ME2xNE46ODJ{IN88US=>	MoHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MZ1-PC	NUe5XVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUTJR\|UxRTFyLkm1O\|Eh\|ryP	MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-CO-1	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWrPeW5kUUN3ME2xNE46QTNzIN88US=>	NUS2boNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
Capan-2	NWXB[\|ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUj2endXUUN3ME2xNU4{OTl6IN88US=>	NEnofoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
697	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVrJR\|UxRTFzLk[3OVch\|ryP	NGPG[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
REH	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PtTWlEPTB;MUGuO\|Q2OSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GI-1	M3i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{C3PWlEPTB;MUGuPFYyPSEQvF2=	NV3RVo82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BB65-RCC	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGn1cZZKSzVyPUGyMlA6OTZizszN	NHu1RWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1651	NF\HV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3TuWGlEPTB;MUKuNlQ4QCEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1618	NHS0c4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mo\GTWM2OD1zMj6zPVc3KM7:TR?=	M3G2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2081	NYXaNGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVnGOnVHUUN3ME2xNk43OTRzIN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GCIY	M{Tnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFrSPWZKSzVyPUGyMlczOTNizszN	M3XWblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NY	NX7Eb29kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWqxWW85UUN3ME2xN{4xPjR\|IN88US=>	M2XWblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PANC-03-27	NHSxXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmizTWM2OD1zMz6wPFA4KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BHY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NI\ZNoVKSzVyPUGzMlIyOjFizszN	NWTVcXdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-OV-3	M3vUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYTuSYZ{UUN3ME2xN{4{PzZ\|IN88US=>	NInQSnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
5637	NXvYSHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\1fpBKSzVyPUGzMlc4PTlizszN	M2\HV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LC-1F	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn;aTWM2OD1zND6wN\|U3KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SNB75	M4S1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmTVTWM2OD1zND6wN\|g{KM7:TR?=	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CHP-212	NX2xNFQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2izSWlEPTB;MUSuNFQ3PCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-1376	MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HWTWlEPTB;MUSuNVEzPiEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6	NUPTXYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoqwTWM2OD1zND6xOVAzKM7:TR?=	NX\xfZdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CA46	NXv1V\|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVjqe\|hFUUN3ME2xOE4yQDJ5IN88US=>	NGHm[pg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SCC-15	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkKxTWM2OD1zND61OVg{KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ATN-1	NVvtUVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIjWfXNKSzVyPUG0MlY3OjdizszN	MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2405	NEniNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGHBN\|dKSzVyPUG0MlgyPTdizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H716	NWHsW5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4j0bGlEPTB;MUSuPFQ6OyEQvF2=	MlrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW620	M1LadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEnXWmlKSzVyPUG0MlkxOTRizszN	NV;HcFJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H226	NXjzU\|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUX2NI41UUN3ME2xOE46ODh3IN88US=>	MmDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW962	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2PUbWlEPTB;MUSuPVQ{OiEQvF2=	M2jEOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
KYSE-150	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlH6TWM2OD1zND65OVUh\|ryP	M1:2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
OCUB-M	NGjROmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4K3TmlEPTB;MUSuPVg5OyEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES7	NFjqcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDzTWM2OD1zNT6wPVg1KM7:TR?=	NXy5XFdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1463	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2T4[WlEPTB;MUWuOFIzOyEQvF2=	NInSclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAKI-1	NXnCZXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1LoeWlEPTB;MUWuOVM1PiEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MKN28	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjuTWM2OD1zNT61OFc6KM7:TR?=	NU\KWJJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW13	NXywd21mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWD6OodHUUN3ME2xOU43OThizszN	NWXhfpZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A3-KAW	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUDDUYZ5UUN3ME2xOU46Pjl5IN88US=>	NX7XdWxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LU-65	NEG1bZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mnm2TWM2OD1zNT65O\|Y5KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Calu-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;lSmlEPTB;MU[uNFM3QCEQvF2=	M4PiVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ST486	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn7kTWM2OD1zNj6wOFMyKM7:TR?=	M2DVcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BB30-HNC	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGTvc4VKSzVyPUG2MlEzPDZizszN	NVfTZplRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EGI-1	NV;MfldnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rYSGlEPTB;MU[uOFQ3KM7:TR?=	NHT1eIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SH-4	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITReXFKSzVyPUG2MlQ4OzFizszN	MkDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MN-60	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3QTWM2OD1zNz6yNlk4KM7:TR?=	NG\3[VI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MPP-89	MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVz3[2RCUUN3ME2xO{4zPDV7IN88US=>	NE\Ye5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A2780	NHnlRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MonYTWM2OD1zNz60NVM6KM7:TR?=	MofaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Daoy	NWnsVVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1m1OWlEPTB;MUeuOFY6PSEQvF2=	M1XNc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2126	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{n6dmlEPTB;MUeuOFc4OSEQvF2=	NWXnToQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1563	NInDbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGXhNpRKSzVyPUG3MlQ6OTdizszN	NGPIUpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
8-MG-BA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGPsdYRKSzVyPUG3MlY3PDhizszN	NVj3d4UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
786-0	NX;GWZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWn2NGZzUUN3ME2xO{45OzV\|IN88US=>	M{Tz[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
AM-38	NUj4O4d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3aTWM2OD1zNz65N\|A3KM7:TR?=	M4rpWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-824	NGfnS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPT[mVnUUN3ME2xPE41PDN4IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MEL-30	M1TMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWe0U\|MzUUN3ME2xPE42ODh{IN88US=>	M4DkOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CESS	NEPUUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLyO4ZKSzVyPUG4Mlc3ODlizszN	NVfqU2dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BL-70	NXvPOHo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1[4PGlEPTB;MUiuPFE2PiEQvF2=	NYfMVnp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2170	M4TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlS2TWM2OD1zOD65NVc6KM7:TR?=	M3\4UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HT-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkmzTWM2OD1zOD65PFMh\|ryP	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BOKU	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHnPZVHUUN3ME2xPU4xOzhzIN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HPAF-II	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF\TTJdKSzVyPUG5MlMxOTVizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KGN	M1;ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTF7LkS3OlUh\|ryP	NUHWOHlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MC-CAR	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzSTWM2OD1zOT62N\|E{KM7:TR?=	MmHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BHT-101	M{izNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MULJR\|UxRTF7Lke3O{DPxE1?	MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW1783	NYfTbWJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFrIVGpKSzVyPUG5Mlc5ODZizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KP-N-YN	NGm0UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTJyLkCyOlIh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-165	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoPmTWM2OD1{MD61OVcyKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GOTO	M2X0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH3jS4RKSzVyPUKwMlY1PTFizszN	Mlr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EFM-19	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGPPPWlKSzVyPUKxMlA4OTZizszN	NIHrTnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CTV-1	M32wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEexZ3hKSzVyPUKxMlExPTRizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HEL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUPJR\|UxRTJzLkSyNVYh\|ryP	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNU-C2B	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUTJR\|UxRTJzLkSyOkDPxE1?	M{CwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ECC4	NUT6[Wg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jZ[mlEPTB;MkGuO\|A4KM7:TR?=	M3nh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NEC8	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrHPHdtUUN3ME2yNU45OzZ6IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KMOE-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M33ye2lEPTB;MkGuPFkzOSEQvF2=	MoixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H524	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVr5eZdsUUN3ME2yNk4xQDB6IN88US=>	M{DoR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
WSU-NHL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmPMTWM2OD1{Mj6xOVc4KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SF126	NFvXZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIjSZXJKSzVyPUKyMlI1PjlizszN	Mor5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HOP-92	MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHrpU2VKSzVyPUKyMlMyPjdizszN	NXn2RoRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CTB-1	M36xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn3ETWM2OD1{Mj60Olc4KM7:TR?=	NF;ScVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-270	M{fKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4P5UmlEPTB;MkKuPVM2PyEQvF2=	NUfPSpNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MEL-24	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml;zTWM2OD1{Mz6xPFch\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Calu-3	M3\2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFTrNWdKSzVyPUKzMlIyOjhizszN	MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GAMG	M{TsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUPzeHhXUUN3ME2yN{4zOzZ5IN88US=>	NHe4UoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1573	NWj5ZYROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH2xR25KSzVyPUKzMlc1OTVizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	M1TuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWS5SGl1UUN3ME2yOE4xOTl2IN88US=>	MlTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TK10	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYTJR\|UxRTJ2LkWwNVMh\|ryP	MmDXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB373-MEL-D	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU\YfmFWUUN3ME2yOE43ODZ2IN88US=>	MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KALS-1	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF7wbW1KSzVyPUK0Mlc{OjdizszN	M4fu[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HUTU-80	NYPjWpd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml:0TWM2OD1{NT64NFMzKM7:TR?=	MoPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HuP-T3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPlNWtUUUN3ME2yOk4yPjd2IN88US=>	NYize5psRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
OE19	M2LKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV7JR\|UxRTJ4LkKxOVMh\|ryP	NIfsdXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
J82	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvIbodZUUN3ME2yOk4zPDdzIN88US=>	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
DU-4475	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLITWM2OD1{Nj6zPFE6KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DMS-53	NXv2NmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTJ4LkWxN\|gh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-741	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUW0OWdEUUN3ME2yOk45OzR2IN88US=>	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW48	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFnqc3hKSzVyPUK2Mlg5OiEQvF2=	M{Oye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
IGR-1	NWLTboJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGX2[5ZKSzVyPUK2Mlk{OzRizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
639-V	NGf1NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGXYd45KSzVyPUK3MlAzPDVizszN	M{[0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LK-2	NVTBWVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MknOTWM2OD1{Nz60NVQyKM7:TR?=	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2347	NHO1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF:zcIRKSzVyPUK3Mlk3QTlizszN	MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2228	NVvLS4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF;neWhKSzVyPUK4MlA6ODVizszN	NXvHcIUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LS-123	NVL3W5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXrJR\|UxRTJ6LkGyOlIh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
U031	NWTYW5kzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NET3XoRKSzVyPUK4MlI2OiEQvF2=	NEe4N5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1792	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MULJR\|UxRTJ6LkS3NlEh\|ryP	NIqwTY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2087	NIXVNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvmeZdFUUN3ME2yPE44PTV{IN88US=>	NEXZTXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2342	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;ROWlEPTB;MkmuOVIxQCEQvF2=	NHPZRYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW626	NYeySWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIjPbGRKSzVyPUK5Mlc2PiEQvF2=	NHvqcXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NIXJTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIfqeplKSzVyPUK5MlgyPSEQvF2=	NG\Jfog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
RXF393	NWfVOolxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWTiSoNyUUN3ME2zNE4xQTV{IN88US=>	NILXRWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LC4-1	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUWwRYN3UUN3ME2zNE4{ODl{IN88US=>	MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1694	NFTkbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX7JR\|UxRTNyLk[2NlQh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
K5	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUDJR\|UxRTNyLkm3NFIh\|ryP	MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HDLM-2	M1OwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYjae4NkUUN3ME2zNE46PzJ3IN88US=>	NYLjepJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BCPAP	M2Hhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEHwRY1KSzVyPUOxMlg{PzlizszN	NUPiVohyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BC-3	NWj5Ro5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTN{LkG0NFMh\|ryP	NVzpO4UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB996-RCC	NVHBeWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX;ENWZYUUN3ME2zNk4zOzV6IN88US=>	M1jhdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2009	M{X3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MU\JR\|UxRTN{LkS5PFEh\|ryP	NV\GdIV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HTC-C3	M1fGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moj5TWM2OD1\|Mz63OVE6KM7:TR?=	MlPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LAMA-84	M2fDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH6zVmFKSzVyPUO0MlQ1ODdizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NFzhc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF[wOXJKSzVyPUO0MlU4OTVizszN	NES3dnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
AN3-CA	M4n6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXWzPHA{UUN3ME2zOU4xPTZ6IN88US=>	NFK1XpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1734	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1ntVGlEPTB;M{WuNlU3OSEQvF2=	NULNUlU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
Ca-Ski	M4HQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4r4OWlEPTB;M{WuOFExOSEQvF2=	NYXpeXRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
U-266	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX7JR\|UxRTN3Lk[xNVQh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SBC-5	M1jWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUTlPXVRUUN3ME2zOU44PzhzIN88US=>	NY\pSVZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GT3TKB	M1rmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLiTWM2OD1\|Nz6xNVUh\|ryP	Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MDA-MB-175-VII	NX\Nc2Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XHUGlEPTB;M{euNlI1QCEQvF2=	NFPhd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
PFSK-1	NF;uT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPWTWM2OD1\|Nz6yOFM2KM7:TR?=	NWfZSmJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
IMR-5	M1TYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIDibXVKSzVyPUO3MlI1QDdizszN	NYHHdoI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
Daudi	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkfBTWM2OD1\|Nz6zOVk4KM7:TR?=	NWPQTZh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A498	NXnYUHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUnFSoxwUUN3ME2zO{44OjF6IN88US=>	NYe2TZVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SCC-4	NFzSRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1vUd2lEPTB;M{euO\|g1OyEQvF2=	MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-680N	NWjoS5NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYnlSphuUUN3ME2zPE4zQDh3IN88US=>	M3;jcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-MES-1	NGTCeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWPJR\|UxRTN6LkOyNVUh\|ryP	NYHlR5BtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SR	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGf1N49KSzVyPUO4MlU1QTVizszN	M2j0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LNCaP-Clone-FGC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\Y[ZZKSzVyPUO4MlU3OzdizszN	Mn3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-HEP-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3vRoZKSzVyPUO4Mlc5OjJizszN	NIHIRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BPH-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEXjN\|JKSzVyPUO4Mlg{OjlizszN	NX73OJBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1755	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mnr5TWM2OD1\|OT61PFE4KM7:TR?=	NWfqS\|lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LXF-289	NYTh[Zk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXLJR\|UxRTN7LkiwPFQh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW1088	NUXLXm86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFvyd45KSzVyPUSwMlIyODdizszN	M2DCdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MOLT-4	NYDvOIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXXrRWI1UUN3ME20NE4zQTBzIN88US=>	Mn:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
AsPC-1	NHLKe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnHPTWM2OD12MD60OVg{KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HOP-62	M1PWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVLJR\|UxRTRyLk[1Olgh\|ryP	NUm3SY9xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A172	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4P4TWlEPTB;NECuPFUyOSEQvF2=	M1vocFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SN12C	NXu1dnNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2HVPGlEPTB;NECuPVM5PSEQvF2=	MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MDA-MB-231	M2\3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrGVlRKSzVyPUSwMlk5QThizszN	NVviTHNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RPMI-2650	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LGemlEPTB;NEGuNVU6OyEQvF2=	NHf3UlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-140	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH:0WmRKSzVyPUSxMlgyOjNizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KINGS-1	NF:1ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfmSoFJUUN3ME20Nk41Pjl5IN88US=>	M2rQWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HSC-3	NWHiXlE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTR{Lk[2OlEh\|ryP	M2mwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PC-14	NV76OG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3FTWM2OD12Mz6xPFgzKM7:TR?=	M4TFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COR-L105	M1v5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHsTWM2OD12Mz62OVAzKM7:TR?=	MkX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BE-13	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\1SWlEPTB;NESuNlM4OSEQvF2=	MkHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H661	NGX0NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUXJR\|UxRTR2LkK5OVgh\|ryP	NXfwOmp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
IST-MEL1	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWnJR\|UxRTR2LkO1PVkh\|ryP	NEHIfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HCC1806	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFv4VndKSzVyPUS0MlU5PzNizszN	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-800	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{TvXGlEPTB;NESuPFQ2OyEQvF2=	NYDZR\|hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
IST-SL2	NIHm[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjLenhKSzVyPUS1MlEzPDdizszN	NXLLSolDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
8305C	NUfPTohkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEWx[4JKSzVyPUS1MlMxQSEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
UACC-62	M2qyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUjSfI9OUUN3ME20Ok4zQDd3IN88US=>	Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COR-L23	M3PVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLYUpU1UUN3ME20O{4yQTlizszN	NYLyNoxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EFE-184	M4HZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzMS2lKSzVyPUS3MlM5QCEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DMS-114	NGCzTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LaOmlEPTB;NEeuOFE1QSEQvF2=	NIHyRZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-520	M2H1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYXJR\|UxRTR6LkWzNVUh\|ryP	NUK2doFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNG-M	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVnJR\|UxRTR7LkSzOEDPxE1?	NWC2VW02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A2058	NH;KelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFH5S5VKSzVyPUS5MlQ5QDVizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HEK293	NEjWT\|JHfW6ldHnvckBie3OjeR?=	MlTUOlAhdWmwcx?=	MXjJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIFnHSk0yKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNicILleJJm[XSnZDDmc5IhPjBibXnud{Bnd2yub4fl[EBjgSCLR1[tNUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkAyOCCvaX7zJIJ6KHG3YX70bZRifGm4ZTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMtKEmFNUCgQUAxNjByMkig{txONg>?	Mn;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
Ba/F3	MYjGeY5kfGmxbjDhd5NigQ>?		MWnJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIFnHSk0yKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxKD1iMD6wNFc3KM7:TT6=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl3MUe1N{c,OjZ7NUG3OVM9N2F-
HEK293	NUTJRZhsTnWwY4Tpc44h[XO\|YYm=	NWTsemlIPjBibXnudy=>	NUS5N\|VqUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBqdnO3bHnuJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDmc4xtd3enZDDifUBKT0ZvMTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjCxNEBucW6\|IHL5JJF2[W62aYTheIl3\SCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlAyPiEQvF2u	NGfmb\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
A431	MmL4SpVv[3Srb36gZZN{[Xl?		NIPsdJFKdmirYnn0bY9vKG:oIFnHSlFTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlAyQCEQvF2u	MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|NE[2OVUoRjJyM{S2OlU2RC:jPh?=
3T3	MVXGeY5kfGmxbjDhd5NigQ>?		MULJcohq[mm2aX;uJI9nKGi3bXHuJGlITjGUIHX4dJJme3OnZDDpckBud3W\|ZTCzWFMh[2WubIOgZpkhTUyLU1GgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{NDFOwG0v	M2LGZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkWxPFI1Lz5{MUK1NVgzPDxxYU6=
NIH 3T3	NFvX[ppHfW6ldHnvckBie3OjeR?=	NVLsUVBFOiCqcoO=	NV7nO4NFUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDJS2YuOVJib4\ldoV5eHKnc4Pl[EBqdiCvb4Xz[UBPUUhiM2SzJINmdGy\|IHHzd4V{e2WmIHHzJGlITjFvaX7keYNm\CCycn;0[YlvKHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKgbJJ{KHC{aX;yJJRwKEmJRkGgbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEG1JI1qdnNiYomgSWxKW0FuIFnDOVAhRSByLkCyOEDPxE1w	MlzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NlEoRjJ2OUCwO\|IyRC:jPh?=
Ba/F3	NHHhO5dHfW6ldHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHnud5VtcW5icnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTBiPTCwMlEzPiEQvF2u	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
A673	NYPi[4t6eUiWUzDhd5NigQ>?		MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M2PKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NFP0[ItyUFSVIHHzd4F6		NYizWHFVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NYS2WpNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NETPVJNyUFSVIHHzd4F6		M3fSPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NWfHS5Y3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MlTHdWhVWyCjc4PhfS=>		MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NFzie4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MWTxTHRUKGG\|c3H5		M1nLdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	Mk\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M2fHSZFJXFNiYYPzZZk>		NUnHXFM5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MlK5dWhVWyCjc4PhfS=>		Mn6ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NVq3N3h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NVjmXlNVeUiWUzDhd5NigQ>?		NYDLfYFOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	M3zpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NU\rR\|VFeUiWUzDhd5NigQ>?		MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NXPUe\|NkeUiWUzDhd5NigQ>?		NXrqdZRYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	Ml3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NVOyXJdseUiWUzDhd5NigQ>?		M1PmPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	M3;CW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	M3zZfZFJXFNiYYPzZZk>		NUHrZ5p3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M1LaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP, AXL1717) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)